Ultragenyx Pharmaceutical Inc. Earnings

Ultragenyx Pharmaceutical Inc.’s revenue jumped 13.24% since last year same period to $166.5Mn in the Q2 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 19.53% jump in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit jumped 12.65% since last year same period to $-114.95Mn in the Q2 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 23.91% jump in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 22.86% since last year same period to -69.04% in the Q2 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 36.35% jump in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.24 - a 4.62% jump from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.24.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.